E-mail: sales@hlsw-bio.com
 
   
  +86-0510-85629785
   
  sales@hlsw-bio.com
info@hlsw-bio.com
   
  No.138,Mashan Meiliang Road,Hubin, Wuxi,Jiangsu Province,China
 
   
  News Your location: Home -News
 
   
   
Raw material medicine serious excess capacity

Views:890      origin:Administrator      Add time:2014-9-28
..........................................................................................................................................................................................................................................

At present, China's pharmaceutical companies are using the Occident attestation, diversified cooperation, transnational mergers and acquisitions, modeand actively explore the road of internationalization.

As the number of push and export the internationalization process is increasing,the pharmaceutical industry in China through the international certification of enterprises more and more. As of 2013 7 at the end of the month, China USAsubmitted to DMF documents in 1532 copies, raw material of our country to obtain EDQMCOS certification 463, our preparation through Europe, beautiful,day GMP certification of enterprise has 37, through the WHOGMP certificationhas 5 enterprises. The export of these enterprises mainly commissioned processing to overseas way, lack of independent brands and marketing channels, strong dependence on foreign dealers.

As early as in twentieth Century 90 years, some forward-looking pharmaceutical companies started the internationalization tries, but this time, pharmaceutical enterprises internationalization route is more choice to supply its products outside the way. Since 2005, China's pharmaceutical enterprisesinternationalization path began to choose more leapfrog development mode to set up subsidiaries or joint ventures and cross-border M & A in the target country, the acquisition target mainly concentrated in Europe and North Americaand standardize the market, many enterprises in the overseas listing,international awareness gradually improve. Since 2004, there have beenSimcere, Nepstar, Po Ming Kant more than 30 enterprises listed in the USAcapital market, Hengrui medicine, pharmaceutical, pharmaceutical and so on have been American subsidiary companies, engaged in R & D, innovative drugregistration support and international marketing. And our company, humanwellmedicine, medicine - Lu, Jiangshan pharmaceutical etc. through joint ventures to enhance R & D, registration and marketing ability.









Prev:No information!

Next:Bulk raw material export no longer
       
  Add:No.138,Mashan Meiliang Road,Hubin, Wuxi,Jiangsu Province,China
Tel:+86-0510-85629785   Fax:+86-0510-85625359   E-mail:sales@hlsw-bio.com info@hlsw-bio.com
Copyright (c) Wuxi Helen Biotechnology Co., Ltd. All rights reserved    备案号:苏ICP备16043161号